# Sakar Healthcare (NSE: SAKAR) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SAKAR · Pivot · prices to 22 Oct 2026

Sakar Healthcare (NSE: SAKAR) closed at ₹923.90 on 22 Oct 2026, up 2.66% on the day. With a market capitalisation of ₹2,056 Cr, it ranks 1135th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 67.6× trailing earnings, against a return on equity of 9.4% in FY26. Over the past year the share price has risen 156.4%. Its 52-week range is ₹352.00 (27 Oct 2025) to ₹1,229.85 (23 Sep 2026); the last close is 24.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹73 Cr (+38.4% year on year) and net profit ₹10 Cr (+120.1%), on a consolidated basis. Promoters held 52.52% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹923.90 |
| Market cap | ₹2,056 Cr |
| P/E (trailing) | 67.6 |
| ROE | 9.4% (FY26) |
| ROCE | 12.8% (FY26) |
| Debt to equity | 0.17 |
| 52-week high | ₹1,229.85 (23 Sep 2026) |
| 52-week low | ₹352.00 (27 Oct 2025) |
| 1-year return | +156.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹73 Cr | +38.4% | ₹10 Cr | +120.1% | ₹4.62 |
| Q4 FY26 | ₹71 Cr | +41.5% | ₹11 Cr | +91.3% | ₹4.96 |
| Q3 FY26 | ₹70 Cr | +62.0% | ₹10 Cr | +126.3% | ₹4.59 |
| Q2 FY26 | ₹58 Cr | +34.5% | ₹5 Cr | −5.4% | ₹2.03 |
| Q1 FY26 | ₹53 Cr | +28.2% | ₹5 Cr | +93.8% | ₹2.11 |
| Q4 FY25 | ₹50 Cr | +16.7% | ₹6 Cr | +84.6% | ₹2.66 |
| Q3 FY25 | ₹43 Cr | +16.6% | ₹5 Cr | +118.8% | ₹2.08 |
| Q2 FY25 | ₹43 Cr | +25.5% | ₹5 Cr | +31.9% | ₹2.17 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹178 Cr | ₹18 Cr |
| FY24 | ₹153 Cr | ₹12 Cr |
| FY23 | ₹133 Cr | ₹13 Cr |
| FY22 | ₹128 Cr | ₹15 Cr |
| FY21 | ₹95 Cr | ₹11 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 52.52%
- Foreign institutions: 12.13%
- Domestic institutions: 11.37%
- Non-institutions: 23.98%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Medi Assist Healthcare Services](https://app.pivotnow.in/stock/MEDIASSIST) | ₹291.75 | ₹2,179 Cr | 24.1 | — |
| [Syncom Formulations (India)](https://app.pivotnow.in/stock/SYNCOMF) | ₹22.83 | ₹2,146 Cr | 28.2 | — |
| [Indoco Remedies](https://app.pivotnow.in/stock/INDOCO) | ₹230.55 | ₹2,128 Cr | — | — |
| [Panacea Biotec](https://app.pivotnow.in/stock/PANACEABIO) | ₹335.85 | ₹2,057 Cr | — | — |
| [Sai Parenterals](https://app.pivotnow.in/stock/SAIPARENT) | ₹461.90 | ₹2,041 Cr | 103.6 | — |
| [Beta Drugs](https://app.pivotnow.in/stock/BETA) | ₹1,773.00 | ₹1,966 Cr | 43.4 | — |

## Questions and answers

### What is the share price of Sakar Healthcare today?

Sakar Healthcare (NSE: SAKAR) last closed at ₹923.90 on 22 Oct 2026. Its 52-week high is ₹1,229.85 and its 52-week low is ₹352.00.

### What is the market cap of Sakar Healthcare?

Sakar Healthcare's market capitalisation is ₹2,056 Cr (₹2,056 Cr) at the 22 Oct 2026 close, ranking 1135th among the NSE companies Pivot tracks.

### What is the P/E ratio of Sakar Healthcare?

Sakar Healthcare trades at a trailing P/E of 67.6. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 43.4.

### What is the ROE and ROCE of Sakar Healthcare?

Return on equity was 9.4% in FY26 and return on capital employed was 12.8% in FY26 (consolidated figures).

### Is Sakar Healthcare a debt-free company?

No. Sakar Healthcare's debt-to-equity ratio was 0.17 in FY26, with total debt of ₹31 Cr.

### What were Sakar Healthcare's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Sakar Healthcare reported revenue of ₹73 Cr, +38.4% year on year, and net profit of ₹10 Cr, +120.1% year on year.

### How has Sakar Healthcare stock performed over the last year?

Sakar Healthcare's share price has risen 156.4% over the past year, +11.2% over three months and −20.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Sakar Healthcare?

As of 30 Jun 2026: promoters 52.52%, foreign institutions 12.13%, domestic institutions 11.37%, non-institutions 23.98%.

### Who are Sakar Healthcare's competitors?

The listed Pharma & Healthcare companies closest to Sakar Healthcare by market cap are Medi Assist Healthcare Services, Syncom Formulations (India), Indoco Remedies, Panacea Biotec, Sai Parenterals and Beta Drugs.

### Is Sakar Healthcare a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Sakar Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAKAR against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.